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Abstract 
 Chronic and end stage renal disease (ESRD) have reached pandemic levels and pose a substantial 
public health burden.  Unfortunately, available therapies lack efficacy in preventing progression to its end 
stage phase.  Regenerative medicine promises to restore function of diseased organs among which the 
kidney, through two possible approaches: firstly, the maximization of the innate ability of tissues to repair 
or regenerate following injury; secondly, the ex vivo bio-fabrication of the organ in question.  When 
regenerative medicine is applied to the setting of chronic or ESRD, it is intuitive that the development and 
employment of strategies to enhance renal repair, promote the generation of new nephrons in the damaged 
kidney, or manufacture transplantable kidneys, could have a major impact on the management of this 
pandemic.  Among the different regenerative medicine technologies currently under development, the so 
called cell-on-scaffold seeding technology (CSST) – whereby cells are seeded in- or onto supporting 
scaffolding biomaterials – seems to offer the quickest route to clinical application.  In this review, we 
illustrate the state of the art of investigations in the field of CSST aiming at restoring kidney function. 
 
 
1. Introduction. 
 As of March 6th 2016, 121,576 patients are registered on the organ transplant waiting list in the US 
(https://optn.transplant.hrsa.gov/, accessed on April the 15th 2016).  This number increases by 5% every 
year, with one more patient being added to the list every ten minutes.  In 2015, 30,973 transplants were 
performed and they were made possible by the generous consent granted from families of 15,064 donors.  
On average, 21 people die every day, while waiting for a transplant.  Moreover, because transplantation 
can often be the solution to many of the diseases associated with aging, the hidden demand is estimated to 
be far beyond current levels.  It therefore becomes evident that the lack of donor organs is considered a 
major health crisis that dramatically impacts the finances of any given country, if we consider that the 
market for organ failure treatments is estimated at about $80 billion per year.  Importantly, this critical 
situation has been a major driving force behind the rise of regenerative medicine (RM) in the past 
decades.  This term refers to a field within the health sciences that aims at repairing, regenerating or 
replacing functionally impaired human cells, tissues, or organs to ultimately restore or establish normal 
function (Katari et al., 2015).  The process of regenerating body parts can occur in vivo or ex vivo, and 
may require cells, natural or artificial scaffolding materials, growth factors and gene editing, or 
combinations of these elements (Orlando et al., 2011).  Given the immense potential that RM has shown 
to meet the most urgent needs of organ transplantation, RM is becoming a field of major interest and 
research investment for the transplant community (Orlando et al, 2013; Orlando and Walker, 2014; 
Rogers et al., 2015), as well as for related specialties of health sciences like nephrology (Morales et al., 
2014).  
 Chronic and end stage renal disease (ESRD) have reached pandemic levels and pose a substantial 
public health burden (Liyanage et al., 2015).  Unfortunately, etiology and pathophysiology are unclear 
and treatment is often inadequate. Ideally, patients with chronic kidney disease should receive treatment 
strategies aimed at counteracting disease causes and mechanisms and enhancing intrinsic processes of 
repair and regeneration. For patients with ESRD, the best treatment option is kidney transplantation, 
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which nevertheless, is dramatically limited by an inadequate supply of transplantable grafts and by the 
heavy toxicity related to lifelong immunosuppression. 
 Tissue engineering is a subfield of RM that aims at restoring function of diseased organs mainly 
through two possible approaches: firstly, the maximization of the innate ability of tissues to repair or 
regenerate following injury; secondly, the ex vivo bio-fabrication of a diseased organ.  When tissue 
engineering is applied to the setting of chronic or ESRD, it is intuitive that the development and 
employment of strategies to enhance renal repair, promote the generation of new nephrons in the damaged 
kidney, or manufacture transplantable kidneys, could have a major impact on the management of this 
pandemic. 
 
2. Tissue engineering approaches to kidney repair, regeneration and replacement 
 The technologies that are currently being developed in order to meet the ultimate objectives of kidney 
tissue engineering – namely, repair, regeneration and replacement of terminally diseased kidneys with 
new functioning ones – may be scholastically subtyped in five categories: cell-on-scaffold seeding 
technology (Salvatori et al., 2014), developmental biology, stem cell, 3D printing and kidney-on-a-chip 
technology (Table 1). 
 
2.1. Cell on scaffold seeding technology (CSST) 
 This technology is centered upon the idea to regenerate the cellular compartment of a given tissue or 
organ, via the seeding of cells on- or into supporting scaffolding material.  The rationale for this lies on 
the evidence that ECM’s molecular, physical and architectural characteristics are critical in the 
determination, differentiation, proliferation, survival, polarity, welfare and migration of the cells of any 
given tissue.  In other words, cells do well only when they reside in their natural niche represented by the 
innate ECM that Mother Nature has engineered for them.  
 Scaffolds may be either synthetic or natural.  Natural scaffolds are obtained from animal (including 
human) organs through a process called decellularization, whereby the cellular compartment of the organ 
in question is destroyed and cell remnants are cleared from the remaining extracellular matrix (ECM) 
scaffold. The rationale for using natural scaffolds lies on the evidence that the ECM is the sine qua non 
for the life of multicellular animal organisms, as it defines the physical and chemical interactions that 
control cellular physiology and fate, and provides mechanical and structural support to cells and tissues 
(Hynes, 2009).  As the synthetic scaffolds lack these critical characteristics, ECM scaffolds represent the 
ideal platform for CSST (Badylak et al., 2011; Badylak et al., 2012).  
 
2.2. Developmental biology 
 The overarching goal of developmental biology technologies is the fabrication of tissues and organs 
through the recapitulating ex utero of the different steps of organ ontogenesis that occur in utero.  To date, 
our understanding of organogenesis is based on mammalian animal models, on the assumption that the 
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conservation of genes across species allows for deducing knowledge of human development from animal 
models (Little MH 2016).  However, while the ability of animal models to be predictive for humans 
remains to be demonstrated (Shanks et al., 2009), organ development is an extremely complex process 
whereby primordial cells differentiate, migrate, proliferate and grow, in an extremely fascinating and 
spatial-temporally  controlled manner.  Moreover, organogenesis is orchestrated by physical, molecular 
and cellular cues that unfortunately remain largely unknown, and takes place in an environment – the 
uterus – whose architecture and physiology cannot be reproduced by any of the currently available 
bioreactors.  Nevertheless, recent investigations have shed light on some developmental mechanism 
regulating the preferential induction of collecting duct versus kidney mesenchyme progenitors, and have 
ultimately led to the generation of functioning renal organoids with potential future applications like 
nephrotoxicity screening, disease modelling and as a source of cells for therapy (Takasato et al. 2015). 
 
2.3. Stem cell 
 The conceptual foundation of this technology lies on the ability of stem cells to give rise to cells of 
the same type, as well as to cells with a different phenotype.  Stem cells can be identified at all stages of 
life of any given biological entity, including humans, however their stemness potential weakens from the 
earlier stages of life throughout senescence.  Embryos contain stem cells with the highest stemness 
potential and have the formidable ability to generate all cells of the mature organism. On the other hand, 
adult stem cells are specific to a given tissue and their stemness is limited to the ability to generate only 
the cells of the tissue in question.  Some stem cells can also differentiate into cells outside their normal 
repertoire of differentiation for the location where they are found, so giving rise to tissues and organs 
other than the one in which they reside; for example, bone marrow stem cells can differentiate into bone, 
cartilage and adipose tissue.  In the past decade, a groundbreaking technology has identified a new type of 
stem cell with a huge potential for clinical application – namely, induced pluripotent stem cells – that can 
be generated from adult, already committed cells through gene reprogramming (Takahashi and 
Yamanaka, 2015).  Finally, stem cells are also characterized by remarkable anti-inflammatory and 
immune-modulatory properties for which their use is being proposed in a myriad of clinical settings 
whereby the mechanisms of disease are inflammatory or immune-mediated. 
 The working hypothesis that justifies the stem cell approach to kidney repair and regeneration is that, 
in the case of acute or chronic reversible damage of a given tissue, the damage may be repaired through 
the activation of the dormant stem cells residing within a specific niche of the tissue in question.  In the 
case of kidney bioengineering, stem cells may represent a valuable source of cells for the reconstitution of 
the cellular compartment of any tissue. 
 
2.4 3D printing 
 3D bioprinting is an emerging technology that facilitates the layer-by-layer precise positioning of 
biological materials, biochemicals and living cells, with the ultimate goal of fabricating viable and 
functioning tissues and organs destined to replace terminally diseased counterparts (Murphy and Atala, 
2014; Peloso et al., 2015). 3D bioprinting has already been used for the precise construction of 
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microfluidic devices in the setting of organ-on-a-chip (see below), as well as for the generation and 
transplantation of multiple tissue types, including multilayered skin, bone, vascular grafts, tracheal 
splints, heart tissue and cartilaginous structures.  Although 3D printing of an anatomically and 
physiologically complex organ such as a kidney is currently beyond our capabilities at the required scale, 
one approach that seems to be promising is the generation of ‘mini-tissue’ building blocks that contain all 
of the functional components of the kidney and can theoretically be combined in a series of repeating 
functional units connected via a vascular and tubular network.  Mini tissues can be fabricated and 
assembled into the larger construct by rational design, self-assembly or a combination of both.  For 
instance, Organovo has recently disclosed the 3D printing of kidney proximal tubular tissue using 
multiple cell types among which fibroblasts, endothelial cells and renal proximal tubular cells. This tissue 
was fabricated without any ECM and was able to survive in vitro for 2 weeks 
(http://3dprintingindustry.com/2015/04/01/organovo-announces-its-first-3d-bioprinted-kidney-tissue/ 
accessed on April 30th, 2016). 
 
2.5 Kidney on-a-chip 
 Chips are 3D microfabricated patterns and structures that closely mimic organ-specific 
microarchitecture and function in vitro (Peloso et al., 2015).  Briefly, chips consist in the patterning of 
fine channels in microfluidic devices that can be attached to fluid pumps and analytical probes and are 
seeded with tissue/organ functional cell types.  Chip technology has been recently developed to replicate 
the complex organ-specific cellular and structural organization of a given tissue or organ, in order to fully 
recapitulate its physiology and function, and represents a major advancement from 2D culture 
methodology. A kidney-on-a-chip can theoretically mimic the structural, mechanical, transport, 
absorptive, and physiological properties of the human kidney (Wilmer et al., 2016), yet the goal of fully 
recapitulating the human kidney structure and function is still a long way away. A system that is capable 
of fully mimicking all key aspects of kidney function will require both tubular and glomerular 
components together with a functional vascular network, combined with proper compartmentalized fluid 
flow. This technology is discussed in more detail by Nieskens and Wilmer in this issue of European 
Journal of Pharmacology. 
 
3. CSST applied to kidney bioengineering 
 To date, CSST has been the main technology implemented in the manufacturing of body parts that 
could be eventually implanted in more than 200 patients, as well as in the experimental attempt to 
generate complex modular organs like the kidney (Orlando et al., 2013; Montserrat et al., 2016).  CSST 
using ECM based scaffolds seems therefore to offer the quickest route to clinical application probably 
because the 3D framework of the innate ECM scaffolds holds all cues necessary for cells to be viable and 
functional.  As a corollary, the native ECM of a given organ should represent the ideal template for all 
regenerative medicine and tissue engineering technologies that aim to replicate the cellular niche as sine 
qua non for tissue and organ bio-fabrication. 
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 Renal ECM is an interlocking meshwork of gylcosaminoglycans, nidogen/entactin, and fibrous 
proteins like collagens, fibronectins, and laminins.  Soluble signals, including cytokines, growth factors, 
and chemokines, are embedded within the ECM and together with fibrous proteins orchestrate cellular 
behaviors, including cell survival, proliferation, migration, and differentiation.  The renal ECM is a very 
dynamic structure and different compartments show site-specific unique compositions of extracellular 
macromolecules designed to support the underlying functional needs of distinct nephron segments 
(Petrosyan et al., 2016).  Over a decade of research in kidney tissue engineering has shown that ECM 
scaffolds can be successfully and consistently produced from virtually all species including humans, are 
completely acellular and virtually non-immunogenic, maintain their architecture and essential molecular 
composition, lack cell membrane molecules, are able to determine cell phenotype and induce genes of 
renal development, possess remarkable angiogenic properties as demonstrated by the ability to induce 
vessel formation in the chorioallantoic membrane, are biocompatible in vitro and in vivo, and, when 
repopulated with renal cells, are able to show some function (Peloso et al, 2015; Petrosyan et al., 2015; 
Petrosyan et al., 2016). Moreover, when acellular porcine renal ECM scaffolds are implanted in pigs, the 
framework of the innate vasculature remains well preserved and is able to  sustain physiologic blood 
pressure (Orlando et al., Ann Surg 2012). 
 
3.1 Rodent models 
 In 2009, Ross et al. (Ross et al., 2009) were the first in reporting that the infusion of a detergent based 
solution throughout the vascular pedicle allows the complete clearance of the cellular compartment of rat 
kidneys, while the innate ECM structure and architecture remain quite preserved.   The decellularization 
protocol was based on 5-days of continuous perfusion with ionic and non-ionic detergents, sodium 
chloride, deionized water and DNase through the renal artery at a pressure of about 100 mmHg.  The 
measures of outcome evaluated by authors were the complete decellularization of the native kidney in 
combination with the preservation of the 3D framework of the ECM, as well as of its basic components 
like collagen IV and laminin.  This was assessed with some straightforward histological tests which 
confirmed the absence of any cell or cell debris, while serial staining showed the presence of a solid 
network of collagen and laminin fibers.  No information about the quantitation of DNA, collagen, 
laminin, elastin or glycosaminoglycan (GAG) after decellularization was provided, and it was not 
determined whether any detergent remained within the acellular scaffolds.  Moreover, authors seeded 
scaffolds with embryonic stem cells, by direct anterograde injection through the artery and direct 
retrograde injection through the ureter. Interestingly, primitive precursor cells attached, populated and 
proliferated ubiquitously within the glomerular, vascular, and tubular structures.  Very importantly, these 
authors made the fundamental observation that these cells had changed their phenotype by the end of the 
first week.  In fact, the evidence that the ECM of a given organ is able to induce the expression of genes 
critical for the development of the organ in question, is of paramount relevance in regenerative medicine 
and is consistent with Bissell’s early intuition of the “dynamic reciprocity” between the ECM on the one 
hand and the cytoskeleton and the nuclear matrix on the other hand, that represents one of the milestones 
in the history of ECM biology (Bissell et al. 1982).  On the wake of these successful preliminary 
investigations, in 2012 the same group provided evidence that pluripotent precursor cells seeded into rat 
renal ECM acellular scaffold vasculature differentiate into endothelial cells, which in turn follow a 
normal ontogeny as they remodel the laminin and collagen of their basement membranes (Ross et al. 
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2012).   These authors first tested vascular cell endothelialization by endothelial specific BsLB4 lectin 
and anti-VEGFR2 (Flk1) antibodies; then, the remodeling of the matrix basement membranes from rat to 
mouse (referred to as “murinization”) was assessed by a monoclonal antibody specific for mouse laminin 
β1 chain. Later, in an elegant study where biocompatible acellular ECM scaffolds could be obtained 
through continuous infusion of SDS (sodium dodecylsulfate) into rat kidneys for only 17 hours, 
Remuzzi’s group observed the loss of cell pluripotency and the start of differentiation towards the meso-
endodermal lineage (Bonandrini et al. 2014). 
 This work paved the way for different protocols to optimize the decellularization process, as well as 
to reconstitute the parenchymal and vascular compartment of the kidney in the rat model.  A milestone 
paper appeared in Nature Medicine in 2013 by Ott and co-workers, who reported the successful seeding 
of acellular rat scaffolds with rat neonatal kidney cells to reconstitute the parenchymal cell compartment, 
and with human umbilical venous endothelial cells to reconstitute the endothelium and allow implantation 
(Song et al., 2013). These authors combined antegrade seeding of endothelial cells with retrograde 
seeding of the kidney cells under the application of a transrenal pressure gradient in an ad hoc designed 
bioreactor.  Cells were able to spread throughout the 3D framework of the scaffold, repopulate half of the 
glomeruli and could be found in different segments of the nephrons across the scaffolds while expressing 
tissue-specific markers. Furthermore, the partially recellularized kidney scaffolds were assessed for 
function both ex vivo and in vivo. Ex vivo, authors demonstrated some degree of filtration capacity when 
compared to acellular ECM scaffolds and cadaveric kidneys; moreover, parameters including vascular 
resistance, albumin retention and glucose reabsorption were lower in the regenerated kidneys when 
compared with intact kidneys procured from dead rats.  In vivo, the group grafted the regenerated kidneys 
orthotopically into recipient rats and showed that urine-like solution could be produced although at lower 
levels than in native kidneys; furthermore, creatinine, urea and albuminuria were lower than in native 
kidneys but higher than in decellularised kidneys in control animals.  This study, just like Ross’s first 
paper, represents a milestone in the literature, which is of interest for the following three reasons: first, 
because for the first time it reported on the development of a dedicated technology that may be applied to 
regenerate – or bioengineer – both cellular compartments (endothelium and parenchymal) of the kidney; 
second, because for the first time, authors very bravely attempted to address the question of how to 
restore the function of renal organoids both in vitro and in vivo; third, because it emphasized the role of 
bioreactors as well as of seeding strategies aimed at reconstituting the cellular compartment (Peloso et al., 
2015). 
 Function was studied by the group at Shandong University, China (Guan et al., 2015), which also 
assessed the amount of critical growth factors as a measure of outcome of their decellularization method.  
Wertheim’s group evaluated growth factors as well, while attempting the optimization and critical 
evaluation of decellularization strategies to develop renal extracellular matrix scaffolds as biological 
templates for organ engineering and transplantation (Caralt et al, 2015).  Moreover, for the first time his 
group reported on the use of human iPSC-derived endothelial cells and tubular epithelial cells to 
repopulate their biomatrix obtained with Triton/SDS-based solution.  
 A pressure gradient to recellularize rat scaffolds was also attempted by Hachisuka et al. (Hachisuka et 
al., 2015). These authors placed the scaffolds in a custom-built device that could remove air to create a 
vacuum. Recellularization was done through direct injection of cells in the artery and the ureter. By 
applying different pressure gradients, an increase of engrafted cells was observed in both the vessels and 
8 
 
the parenchyma, although seeding of the parenchyma seemed to be less efficient. Seeded endothelial cells 
survived and proliferated during 72-hour perfusion culture, and vascular resistance increased along with 
increased cellularity of the kidney scaffolds.  
 
3.2 Porcine models 
 Pigs are known as the most common animal source of clinical xenografts (Baptista et al., 2009) and 
therefore represent the ideal model for clinically relevant investigations in the field of kidney – and, more 
broadly, organ – bioengineering and regeneration. In the attempt to identify a new potentially 
inexhaustible source of organs for transplant purposes, the pig may represent that invaluable source both 
as a source for xenografts, as well as a source for ECM scaffolds (Salvatori et al, 2015). In 2012, Orlando 
et al. reported for the first time the use of porcine kidneys as a source of renal ECM scaffolds for kidney 
bioengineering investigations (Orlando et al., 2012). He showed that ECM scaffolds can be successfully 
and consistently produced from 25 kg female Yorkshire pig kidneys. Such scaffolds are acellular, 
maintain their 3D architecture and molecular composition, show an intact and patent innate vascular tree, 
and are biocompatible both in vitro and in vivo. In fact, when cells are seeded on fragments of ECM, they 
attach and remain viable for 1 week. When acellular scaffolds are implanted in pigs and kept in situ for 2 
weeks, animals tolerate the scaffold well. Importantly, for the first time Orlando et al. provided evidence 
that acellular scaffolds are able to sustain physiological blood pressure despite the absence of muscle cells 
and endothelium in the vasculature. Moreover, it was also noticed that the framework of the innate 
vasculature is resilient and able to respond to modifications of the applied pressure, when the scaffold is 
perfused with solutions. This information is of critical importance in view of translation, and suggests that 
ECM-based scaffolds may be the scaffold of choice in organ bioengineering.  In fact, synthetic scaffolds 
lack the innate vasculature, and no technology is currently capable of reproducing the vascular network of 
any given tissue or organ. Of note, when porcine acellular scaffolds were procured and analyzed with 
H&E staining, as expected, the whole vasculature was filled with thrombi due to the lack of endothelium 
(Orlando et al., 2012). Later on, the same group from Wake Forest published a study showing that 0.5% 
SDS was the most effective solution for decellularizing porcine kidneys (Sullivan et al. 2012). 
 In an attempt to develop strategies to recellularize acellular ECM scaffolds, it is important to 
understand how the ECM interacts with cells.  To address this fundamental question, McNeill et al. 
derived a method to develop region-specific ECM biomaterials (namely, ECM sheets, ECM hydrogels, 
and solubilized ECM) for stem cell culture from the three regions of the porcine kidney – cortex, medulla, 
papilla (O’Neill et al., 2013).  The objective of the study was to determine if there were region-specific 
effects of kidney ECM on the growth and metabolism of kidney-derived stem cells (KSC), how these 
effects depend on the preservation of ECM structure versus composition alone, and if these effects extend 
to exogenous (non-kidney) stem cells, such as mesenchymal stem cells (MSCs).  Interestingly, when KSC 
were seeded on renal ECM and control ECM from other organs, it was found that ECM biomaterials 
derived from the kidney affect the growth and metabolism of KSC with regional specificity.  In particular, 
there is a significant degree of recognition and specificity between adult kidney stem cells and their 
extracellular environment. Stem cells showed significantly higher proliferation and higher metabolic 
activity in kidney ECM when compared to KSCs in ECM from other organs.  In addition, KSCs showed 
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lower proliferation and higher metabolic activity when cultured in papilla ECM (kidney stem cell niche) 
compared to medulla and cortex ECM. 
 Guan et al. (Guan et al., 2015) reported a new method for repopulating ECM renal scaffolds, 
consisting in multiple injections with a 28G needle throughout the porcine kidney. More recently, the 
group at Wake Forest (Abolbashari M et al., 2016) demonstrated the feasibility of seeding porcine 
primary renal cells into whole-renal porcine ECM scaffolds by multiple injections with 23G needles, after 
pre-conditioning of the scaffold prior to seeding by 1-day flushing with a specific culture medium. 
Briefly, renal cells were suspended in media at a concentration of 10 × 106 cells/ml and then delivered 
into the cortical region of the renal scaffolds using a 23G needle. The injections started in the periphery of 
the kidney in the upper pole. The distance between the different injection sites was 2.5 mm with a depth 
of 5 mm. 0.5 ml (5 million cells) of the cell suspension was injected at each site of both the anterior and 
posterior surfaces of the upper pole of the kidney. In total, 400 × 106 cells were injected into each kidney, 
and, at completion of the seeding process, the -seeded scaffolds were incubated statically for 30 min 
before being subjected to perfusion culture for up to 28 days.  During the study, the organoid seemed to 
be viable and exert function.  Reportedly, this method grants repopulation of approximately 40-50% of 
the upper pole of the kidney.  The same group also attempted the regeneration of the endothelium using 
antibodies to bound endothelial cells that were conjugated to the ECM in order to improve retention of 
endothelial cells (Kap KO et al., 2014).  
 
  As the detergents currently used to obtain ECM scaffolds could be damaging to the microstructure of 
the renal tissue and may undesirably solubilize the endogenous growth and signaling factors, some 
authors have tried to optimize the method in order to minimize the damage to the ECM. The group in 
Provo, USA (Poornejad et al, 2016), recently illustrated an automated decellularization method for 
porcine kidneys combining physical and chemical steps. Briefly, freezing/thawing, incremental increases 
in flow rate under constant pressure, applying osmotic shock to the cellular membranes, and low 
concentrations of SDS were used to decrease SDS exposure time during the decellularization process 
from 36 to 5 h, which preserved the microstructure while still removing 99% of the DNA. Importantly, 
GAGs were almost totally preserved, leading to an enhancement of cell-ECM interactions. Human renal 
cortical tubular epithelium cells grew more rapidly when cultured on the ECM obtained from the 
improved decellularization process and also demonstrated more in vivo-like gene expression patterns.  Of 
note, a better preservation of GAGs was also reported by Wang et al. (Wang et al., 2015), whose studies 
also addressed the topic of residual detergent within the scaffolds as well as of whether porcine 
endogenous retroviruses can be detected within the scaffolds. 
 
3.3 Non-human primate models 
 Rhesus monkey kidneys have been proposed by Tarantal’s group as an ideal platform for 
investigations aiming at assessing the role of ECM scaffold in the field of kidney regeneration, repair and 
bioengineering. In their seminal studies, Tarantal et al. have demonstrated that decellularized sections of 
rhesus monkey kidneys of all age groups provide a natural ECM with sufficient structural properties with 
spatial and organizational influences on human embryonic stem cell migration and differentiation 
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(Nakayama et al., 2010; Nakayama et al., 2013; Batchelder et al., 2015), and that the age of the donor is a 
critical factor in repopulation efficiency (Nakayama et al., 2011).  Interestingly, ECM allows formation of 
nephron structures, stores several residual growth factors that may be beneficial in scaffold 
recellularization, and retains antimicrobial proteins that may be beneficial for in vitro culture as well as 
downstream host integration (Nakayama et al., 2011).  
 
3.4 ECM scaffolds derived from the human kidney 
It is envisioned that, when research will deliver the technology to allow fabrication of renal 
organoids with CSST, a patient affected by ESRD will have one of his kidneys removed robotically.  This 
kidney will be thereafter processed in order to obtain healthy cells, as well as an acellular scaffold that 
will serve as template for the bioengineering of his or her new kidney.  This vision has justified the use of 
discarded kidneys as a platform for kidney bioengineering (Katari et al., 2014; Gifford et al., 2015).  Only 
in the US, up to 2,600 kidneys that were initially procured for transplant purposes are eventually 
discarded due to poor biopsy, surgical damage, long preservation, etc. (Orlando et al. 2013).  Orlando and 
colleagues were the first to conceptualize the use of human discarded kidney as a source of ECM 
scaffolds for CSST research, and to show feasibility of application of CSST to the human kidney 
(Orlando et al., 2013; Peloso et al., 2015; Petrosyan et al., 2015).  Investigations showed that SDS-based 
decellularization yields acellular ECM scaffolds, as in the case of the rodent, porcine and non-human 
primate models.  However, the most relevant difference between human and non-human ECM scaffolds is 
that human scaffolds consist of diseased or damaged matrix, which raises concerns about its usefulness.  
However, as evidence of fibrosis reversibility has been provided in a myriad of clinical settings, the use of 
discarded kidneys has become increasingly popular in tissue engineering, as demonstrated by the plethora 
of primary papers on the topic released in the past 5 years. In the case of the human kidney, the work of 
Orlando’s group  has been fundamental in showing that the ECM intrinsic to human organs seems to be 
an extremely useful biomaterial for whole organ bioengineering for several reasons, among which is the 
evidence that they maintain the framework of the innate vasculature which is critical for implantation in 
vivo.  Preliminary investigations have shown that ECM scaffolds can be successfully and consistently 
produced from the human kidney, and display the following key features: they maintain their architecture; 
their gross molecular composition and vasculature is preserved; they lack immunogenic cell membrane 
proteins; and they retain numerous bioactive growth factors that are stored in the 3D structure of the 
ECM, as demonstrated by the fact that they induce angiogenesis in a chorioallantoic membrane assay 
(Orlando et al., 2013; Peloso et al., 2015).  Importantly, when multipotent stem cells are seeded on such 
scaffolds, cells attach well, are able to migrate throughout the 3D framework of the scaffold, remodel the 
ECM, and show the ability to mount an inflammatory response and promote angiogenesis (Petrosyan et 
al., 2015). 
 
4. Challenges to the development of transplantable kidney organoids using acellular ECM scaffolds 
Despite recent progress, CSST has to overcome numerous challenges before it can be translated 
to the clinic. 
First, we need to better understand how the human kidney develops, as well as the mechanisms with 
which the kidney repairs itself after damage.  Worldwide, kidney development has polarized the attention 
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of countless research teams as well as of funding institutions and agencies.  However, due to the inherent 
difficulties associated with investigating the development of human organs, our knowledge of kidney 
development is based mainly on small animal models.    On the other hand, investigations aiming at 
revealing the mechanisms through which the kidney repairs itself are often conducted on patients who are 
experiencing different degrees of renal impairment, so bypassing the biases that may derive from non-
human models. 
Second, when the ex vivo engineering (synonymous with fabrication) of a transplantable kidney 
organoid is considered, current investigations are being conducted without any criteria vis a’ vis of the 
nutrients, oxygen and energy supply required by the new organ to develop.  There is basically no 
information about how much oxygen, nutrients and energy a developing kidney needs to complete its 
maturation and be considered viable.  Indeed, a critical step will be to achieve the maturation of the 
seeded scaffolds in custom made bioreactors, yet long term maturation that recapitulates kidney 
ontogenesis (up to 3 months) has never been reported and is burdened by a high risk of super infection of 
the bio-system.   
Third, reports on the characterization of the different renal ECM scaffolds are scattered, measures of 
outcome are inconsistent, and a unifying vision is missing. Therefore, it will be of paramount importance 
for investigators in the field to unite forces, share experiences and combine assets, specializations and 
visions.  
Fourth, strategies to recellularize ECM scaffolds are still at their early stages, and results are far too 
preliminary.  Moreover, scalability to more clinically relevant models seems hard at the moment. 
Fifth, it remains unclear which cells should be used – progenitor cells with different degrees of 
stemness, adult cells, iPS, etc. – to repopulate acellular scaffolds in order to regenerate the parenchymal 
and vascular compartments. While progenitor cells have a huge potential given their ability to generate 
different cell lineages, the risk of tumourigenesis cannot be ruled out and represents a significant burden 
even if investigations are still far from any clinical applicability.  Even in this case, coordination and 
integration of ad hoc research is desirable and would certainly foster progress.  As a matter of fact, the 
NIH has established the “Re-Building Consortium” (https://www.rebuildingakidney.org/) to support the 
development and implementation of strategies such as de novo repair of nephrons, the re-generation of 
nephrons, and the in vitro engineering of a biological kidney to enhance renal repair and promote the 
generation of new nephrons after damage. 
Sixth, current technology lacks appropriate and efficient bioreactors and mathematical models.   
 
 
5. Conclusions 
 CSST promises to meet the most urgent needs of organ transplantation, namely the identification 
of a potentially inexhaustible source of organs and immunosuppression-free transplantation (Orlando et 
al., 2013).  In fact, the use of autologous cellular material has the potential to obviate the need for lifelong 
antirejection therapies, while de novo organ fabrication a’ la demande using scaffolds of human or animal 
origin could, theoretically, provide a limitless supply of transplantable organs for waiting list patients, 
thus circumventing the challenge of organ shortage. While current technology allows production of 
natural ECM scaffolds from virtually all animal species, a thorough characterization of the renal ECM is 
still missing and the reconstitution of the cellular compartment post decellularization remains too far from 
the realm of the possible.  So far, it seems that cells and ECM do not really integrate in a fully functioning 
12 
 
system, as occurs in nature. Research should aim at  understanding  the mechanisms of interaction 
between cells and ECM, as well as of the role of growth factors of which the matrix is a reservoir. 
Acquisition of in-depth knowledge of the developmental mechanisms of the single organs will be crucial 
for designing appropriate strategies which reproduce, in suitable bioreactors, the key steps of organ 
ontogenesis. 
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